PDCD1 and metastatic colorectal cancer: Our study suggested that an age less than 60 years, in males, without liver metastasis was associated with benefit from treatment with the regorafenib and PD‐1 antibody combination as third‐line treatment for microsatellite stable metastatic colorectal cancer.